|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"heo j"
Showing items 1-22 of 22 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2021-09-04T06:11:39Z |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study
|
Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
|
JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:11Z |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
|
JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T05:17:13Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2020-08-11T08:36:43Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.;Cheng A.-L.;Park J.-W.;Park J.H.;Po-Chin Liang;Hidaka H.;Izumi N.;Heo J.;Lee Y.J.;Sheen I.-S.;Chiu C.-F.;Arioka H.;Morita S.;Arai Y.; Kudo M.; Cheng A.-L.; Park J.-W.; Park J.H.; PO-CHIN LIANG; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2020-05-04T08:06:33Z |
Editorial message: Special track on Operating Systems (OS)
|
Kuo, T.-W.;Heo, J.; Kuo, T.-W.; Heo, J.; TEI-WEI KUO |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 國立成功大學 |
2019 |
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection
|
Wei, L.;Kumada, H.;Perumalswami, Perumalswami P.V.;Tanwandee, Tanwandee T.;Cheng, W.;Heo, J.;Cheng, P.-N.;Hwang, P.;Mu, S.M.;Zhao, X.M.;Asante-Appiah, E.;Caro, L.;Hanna, G.J.;Robertson, M.N.;Haber, B.A.;Talwani, R. |
| 國立成功大學 |
2019 |
Performance improvement of III–V compound solar cells using nanomesh electrode and nanostructured antireflection structures
|
Jian, L.-Y.;Wu, C.-N.;Lee, H.-Y.;Heo, J.;Lee, C.-T. |
| 國立成功大學 |
2019 |
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C-CORAL study
|
Wei, L.;Jia, Jia J.D.;Wang, F.S.;Niu, J.Q.;Zhao, X.M.;Mu, S.;Liang, Liang L.W.;Wang, Z.;Hwang, P.;Robertson, M.N.;Ingravallo, P.;Asante-Appiah, E.;Wei, B.;Evans, B.;Hanna, G.J.;Talwani, R.;Duan, Z.P.;Zhdanov, K.;Cheng, P.-N.;Tanwandee, Tanwandee T.;Nguyen, V.K.;Heo, J.;Isakov, V.;George, J.;Investigators, on behalf of the C-CORAL |
| 臺大學術典藏 |
2018-09-10T18:04:58Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo, M.;Cheng, A.-L.;Park, J.-W.;Park, J.H.;Liang, P.-C.;Hidaka, H.;Izumi, N.;Heo, J.;Lee, Y.J.;Sheen, I.-S.;Chiu, C.-F.;Arioka, H.;Morita, S.;Arai, Y.; PO-CHIN LIANG; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T18:03:51Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
Kao, J.-H.;Yu, M.-L.;Peng, C.-Y.;Heo, J.;Chu, C.-J.;Chang, T.-T.;Lee, Y.-J.;Hu, T.-H.;Yoon, K.T.;Paik, S.W.;Lim, Y.S.;Ahn, S.H.;Isakov, V.;Mcphee, F.;Hu, W.;Scott Swenson, E.;Yin, P.D.;Treitel, M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T14:59:23Z |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study
|
Manns, M.;Pol, S.;Jacobson, I.M.;Marcellin, P.;Gordon, S.C.;Peng, C.-Y.;Chang, T.-T.;Everson, G.T.;Heo, J.;Gerken, G.;Yoffe, B.;Towner, W.J.;Bourliere, M.;Metivier, S.;Chu, C.-J.;Sievert, W.;Bronowicki, J.-P.;Thabut, D.;Lee, Y.-J.;Kao, J.-H.;Mcphee, F.;Kopit, J.;Mendez, P.;Linaberry, M.;Hughes, E.;Noviello, S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T09:21:35Z |
Editorial message: Special track on Operating Systems (OS)
|
Kuo, T.-W.; Heo, J.; TEI-WEI KUO |
| 臺大學術典藏 |
2018-09-10T09:21:35Z |
Advanced issues of operating systems for reliable distributed sensor networks: Aim and scope
|
Hong, J.; Kuo, T.-W.; Heo, J.; TEI-WEI KUO |
| 臺大學術典藏 |
2018-09-10T08:41:17Z |
Special track on Operating Systems (OS)
|
Hong, J.;Kuo, T.-W.;Heo, J.; Hong, J.; Kuo, T.-W.; Heo, J.; TEI-WEI KUO |
| 國立成功大學 |
2018 |
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
|
George, J.;Burnevich, E.;Sheen, I.-S.;Heo, J.;Kinh, N.V.;Tanwandee, Tanwandee T.;Cheng, P.-N.;Kim, D.Y.;Tak, W.Y.;Kizhlo, S.;Zhdanov, K.;Isakov, V.;Liang, Liang L.;Lindore, P.;Ginanni, J.;Nguyen, B.-Y.;Wahl, J.;Barr, E.;Robertson, M.;Ingravallo, P.;Talwani, R.;Investigators, on behalf of the C-CORAL Study |
| 中國醫藥大學 |
2014-11 |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|
(Manns M)*;(Pol S);(Jacobson IM);(Marcellin P);(Gordon SC);彭成元(Cheng-Yuan Peng);(Chang TT);(Everson GT);(Heo J);(Gerken G);(Yoffe B);(Towner WJ);(Bourliere M);(Metivier S);(Chu CJ);(Sievert W);(Bronowicki JP);(Thabut D);(Lee YJ);(Kao JH);(McPhee F);(Kopit J);(Mendez P);(Linaberry M);(Hughes E);(Noviello S) |
| 臺大學術典藏 |
2012 |
Advanced issues of operating systems for reliable distributed sensor networks: Aim and scope
|
Hong, J.; Kuo, T.-W.; Heo, J.; TEI-WEI KUO |
Showing items 1-22 of 22 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
